Biotechnology

Esco Lifesciences Closes a Record-Setting US$200M Series A Round Led by Vivo Capital and Novo Holdings

SINGAPORE, May 27, 2021 /PRNewswire/ -- Esco Lifesciences ("Esco", the "Company") announced today the close of an over-subscribedUS$200 million Series A and Crossover round. The financing was led by Vivo Capital and Novo Holdings A/S, with participation from new investors including China Investme...

2021-05-27 09:00 4053

Gannex Received China IND Approval of Its FXR Agonist ASC42 for NASH Indication

SHANGHAI, May 27, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), fully dedicated to the R&D and commercialization of new drugs in the field of non-alcoholic steatohepatitis (NASH), today announces that China National Medical Products Administration (NMP...

2021-05-27 08:30 2869

WuXi Biologics and OncoC4 Establish Exclusive CDMO Partnership

SHANGHAI and ROCKVILLE, Md., May 27, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and OncoC4, Inc., a privately-held, clinical-stage biopharmaceutical company, today announced that the companies have entered ...

2021-05-27 08:30 5206

TransThera announces collaboration with Roche to evaluate TT-00420 as part of a novel combination to treat GI cancers in China

NANJING, China, May 26, 2021 /PRNewswire/ -- TransThera Biosciences Co. Ltd. ( "TransThera" ), a clinical stage biotechnology company dedicated to developing innovative therapeutics across oncology, cardiovascular, and inflammatory diseases with major unmet medical needs globally and inChina,  to...

2021-05-26 21:00 1466

Gracell Biotechnologies Hosting Key Opinion Leader Webinar on High Risk Multiple Myeloma, Treatment Challenges and Dual-Targeting CAR-T with Overnight Manufacturing - a Novel Approach for Treatment of Multiple Myeloma

SUZHOU, China and PALO ALTO, Calif., May 26, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today ...

2021-05-26 21:00 10289

RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19

The two patents protect opaganib and RHB-107 for the treatment of COVID-19 until at least 2041 once granted Enrollment in opaganib's global Phase 2/3 study in hospitalized patients with severe COVID-19 is almost 100% complete RHB-107's ongoing Phase 2/3 study is enrolling U.S. non-hospitalized p...

2021-05-26 19:12 9160

Prosit Sole Biotechnology Initiates First-In-Human Clinical Trial of Novel Interferon Lambda Chimera in US

BALTIMORE, May 26, 2021 /PRNewswire/ -- Prosit Sole Biotechnology, a clinical-stage biotech company developing novel protein therapeutics, today announces that it has initiated the first-in-human ("FIH") Phase I clinical trial of PSP001 in US. PSP001 is a novel, long acting and potent interferon ...

2021-05-26 16:10 1182

I Peace's cell manufacturing facility "Peace Engine Kyoto" receives third-party certification as US cGMP compliant: the facility now meets the standard for both the US and Japanese markets

PALO ALTO, Calif., May 25, 2021 /PRNewswire/ -- I Peace, Inc. (CEO: Koji Tanabe ), aPalo Alto-based biotech start-up focusing on Nobel Prize-winning technology "induced pluripotent stem cells (iPSCs)" received a third-party certification as US FDA cGMP compliant for its manufacturing facility "Pea...

2021-05-26 03:00 1364

OptraSCAN Announces CytoSiA - A Complete Digital Solution For Scanning And Analysis Of Cytology Slides At Affordable Pricing

- OptraSCAN's Intelligent Tool CytoSiA – To Advance Cytology Screening Through Unmatched Image Quality And Artificial Intelligence Based Image Analysis Solution SAN JOSE, Calif. and PUNE, India, May 25, 2021 /PRNewswire/ -- OptraSCAN ®, the leading On-Demand Digital P...

2021-05-25 21:27 2743

Procyrion Announces Successful First-in-Human Cases in Cardiorenal Syndrome (CRS) Patients with Aortix™ Percutaneous Mechanical Circulatory Support Device

Pilot CRS Study to Evaluate Performance of Novel Aortix device in Australia and the U.S. HOUSTON, May 25, 2021 /PRNewswire/ -- Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today successful treatment of the fir...

2021-05-25 19:02 1037

ViewMind Applauded by Frost & Sullivan for Its One-of-a-Kind Digital Biomarker Technology for Neurocognitive Disorders

The AI-powered technology can enable early screening at scale for a range of neurocognitive conditions, such as Alzheimer's and mild cognitive impairment SANTA CLARA, Calif., May 25, 2021 /PRNewswire/ -- Based on its recent analysis of the global market for digital biomarkers for neurocognitive ...

2021-05-25 18:47 1548

IVF Life the first clinic group in Europe to use Artificial Intelligence to non-invasively assess the genetic integrity of embryos

ADELAIDE, Australia, May 25, 2021 /PRNewswire/ -- IVF Life Group, a leading group of IVF clinics acrossSpain, UK, and Germany, will be among the first in Europe to use Artificial Intelligence (AI) to non-invasively assess embryos to determine their genetic integrity. The AI product Life Whisperer...

2021-05-25 17:15 1528

Renowned international investor Jim Rogers joins Life3 Biotech's Board of Investors

SINGAPORE, May 25, 2021 /PRNewswire/ -- Renowned international investor Jim Rogers has joined Singapore-based food tech company, Life3 Biotech (Life3) as a member of its Board of Investors.

2021-05-25 16:30 2336

Seegene reports solid results in the first quarter of 2021 with KRW 351.8 billion

* SEEGENE POSTS KRW 193.9 BIL. IN OPERATING PROFIT, UP 388% ON-YEAR * OPERATING PROFIT RATIO AT 55%, DESPITE CONSTANT INVESTMENT IN R&D AND EMPLOYEES SEOUL, South Korea, May 25, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), a molecular diagnostics company reported its financial results for th...

2021-05-25 15:33 11857

Clinical Trial Application of ASC40 Combined with Bevacizumab to Treat Patients with Recurrent Glioblastoma Accepted by China NMPA

HANGZHOU and SHAOXING, China, May 25, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) today announces that following the consultation with China National Medical Products Administration (NMPA), the clinical trial application of ASC40 combined with bevacizumab to treat patients with re...

2021-05-25 08:30 2741

Antengene Appoints Kathryn Gregory as Vice President and Head of Corporate Business Development

SHANGHAI and HARTFORD, Conn., May 25, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and...

2021-05-25 08:00 3362

SIRONA - The world's first and largest RCT comparing Sirolimus V/S Paclitaxel balloon for the treatment of Peripheral Arterial Disease progresses rapidly

JENA, Germany, May 25, 2021 /PRNewswire/ -- Concept Medical Inc., focused on vascular intervention drug delivery devices, releases status updates ofSIRONA Randomized Control Trial (RCT) which compares head-to-head,SIROlimus versus Paclitaxel Drug-Eluting BallooN...

2021-05-25 07:03 2944

Lifebit Awarded A Four-Year Contract for Hong Kong's Genome Project

Lifebit's precision medicine software will power Hong Kong's development of genomic medicine by supporting the Hong Kong Genome Institute to implement the first large-scale genome sequencing initiative, the Hong Kong Genome Project. The Project will empower medical professionals and researchers t...

2021-05-25 06:00 3071

TruDiagnostic signs an exclusive license agreement with Duke University to use the DunedinPoAm rate of aging algorithm.

LEXINGTON, Ky. and DURHAM, N.C., May 24, 2021 /PRNewswire/ -- Today, TruDiagnostic signs an exclusive license agreement to the DunedinPoAm pace of aging methylation prediction algorithm. Pace of Aging is how quickly a person's epigenetic markers are changing to hasten or slow their progression of...

2021-05-24 20:30 1456

Singapore-based HeMo Bioengineering Receives China's NMPA Approval for flagship Afentta(TM) Aspiration Catheter

SINGAPORE, May 24, 2021 /PRNewswire/ -- HeMo Bioengineering Ltd ("HeMo"), a Singapore-based medical device company with a focus on treating stroke patients, is pleased to announce that its Afentta™ intracranial thrombectomy aspiration catheter – a product developed byHeMo's branch in China – has ...

2021-05-24 20:01 1731
1 ... 241242243244245246247 ... 306

Week's Top Stories